INDIA’s Tata Group on Monday(9) launched a Covid-19 test kit that will process results more easily and faster than the RT-PCR method considered the gold standard for detection, at a time when cases are still rising in the country.
The nasal swab test, developed jointly by Tata and the government, is also more accurate than the rapid antigen test currently favoured in India, the ministry of science and technology said in September.
Tata Medical and Diagnostics, the healthcare arm of the cars-to-clothes conglomerate, will begin manufacturing 1 million kits a month at its plant in the southern city of Chennai and can then scale up rapidly, CEO Girish Krishnamurthy told Reuters.
TataMD CHECK, as the product is called, can return results in 90 minutes and will be sold through hospitals and laboratories from next month with the initial focus being on the home market, Krishnamurthy said.
“You don’t need big, expensive equipment to do the test, so it becomes more accessible and available, and more labs can start testing,” he said.
A process based on artificial intelligence and automation will be used to test swabs, Krishnamurthy said.
India’s Covid-19 cases have risen by 45,903 to 8.55 million in the past 24 hours, government data showed, with the country’s infections lagging only the United States’. Deaths increased by 490 to 126,611.
India does more than 1 million Covid-19 tests a day, nearly 60 per cent of them using the rapid antigen method that is faster but less accurate.
It wants to increase testing to more than 1.5 million a day, though health experts have warned its heavy reliance on the rapid antigen tests that typically detect the virus around 80 per cent to 90 per cent of the time could under-report infections.
Antigen devices return results in about 15 minutes compared with several hours for the reverse transcription polymerase chain reaction (RT-PCR) method.
“Our aspiration is that this can become a new standard in testing,” Krishnamurthy said.
